{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:02:16Z","timestamp":1793408536940,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"DOI":"10.1038\/s41390-026-05586-0","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:46:58Z","timestamp":1792108018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clesrovimab in the new era of RSV prevention: one season, one dose, one chance"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6950-4076","authenticated-orcid":false,"given":"Fajia","family":"Farhath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil","family":"Kumar K","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"5586_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.70257","volume":"36","author":"E Bizot","year":"2025","unstructured":"Bizot, E. et al. Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in-depth review of mechanisms of action, failure factors, and future perspectives. Pediatr. Allergy Immunol. 36, e70257 https:\/\/doi.org\/10.1111\/pai.70257 (2025).","journal-title":"Pediatr. Allergy Immunol."},{"key":"5586_CR2","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1016\/S2214-109X(21)00558-1","volume":"10","author":"C Cohen","year":"2022","unstructured":"Cohen, C. & Zar, H. J. Deaths from RSV in young infants\u2014the hidden community burden. Lancet Glob. Health 10, e169\u2013e170 https:\/\/doi.org\/10.1016\/S2214-109X(21)00558-1 (2022).","journal-title":"Lancet Glob. Health"},{"key":"5586_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf695.733","volume":"13","author":"A Guerra","year":"2026","unstructured":"Guerra, A., Zhang, Y., Railkar, R. A., Lutkiewicz, J. & Sinha, A. Respiratory tract infections and co-infections following administration of the respiratory syncytial virus antibody clesrovimab versus placebo: analysis of the phase 2b\/3 CLEVER trial. Open Forum Infect. Dis. 13, ofaf695.733 https:\/\/doi.org\/10.1093\/ofid\/ofaf695.733 (2026).","journal-title":"Open Forum Infect. Dis."},{"key":"5586_CR4","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2516948","volume":"21","author":"Y He","year":"2025","unstructured":"He, Y. et al. Phase I open-label study of the respiratory syncytial virus monoclonal antibody clesrovimab: safety and tolerability in healthy Chinese participants. Hum. Vaccin Immunother. 21, e2516948 https:\/\/doi.org\/10.1080\/21645515.2025.2516948 (2025).","journal-title":"Hum. Vaccin Immunother."},{"key":"5586_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/25151355241310601","volume":"13","author":"K Kelleher","year":"2025","unstructured":"Kelleher, K., Subramaniam, N. & Drysdale, S. The recent landscape of RSV vaccine research. Ther. Adv. Vaccines Immunother. 13, 25151355241310601 https:\/\/doi.org\/10.1177\/25151355241310601 (2025).","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"5586_CR6","doi-asserted-by":"publisher","first-page":"e478","DOI":"10.1093\/infdis\/jiae581","volume":"231","author":"SA Madhi","year":"2025","unstructured":"Madhi, S. A. et al. A phase 1b\/2a trial of a half-life extended respiratory syncytial virus neutralizing antibody, clesrovimab, in healthy preterm and full-term infants. J. Infect. Dis. 231, e478\u2013e487 https:\/\/doi.org\/10.1093\/infdis\/jiae581 (2025).","journal-title":"J. Infect. Dis."},{"key":"5586_CR7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.15585\/mmwr.mm7432a3","volume":"74","author":"DL Moulia","year":"2025","unstructured":"Moulia, D. L. et al. Use of clesrovimab for prevention of severe respiratory syncytial virus-associated lower respiratory tract infections in infants: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2025. MMWR Morb. Mortal. Wkly Rep. 74, 508\u2013514 https:\/\/doi.org\/10.15585\/mmwr.mm7432a3 (2025).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"5586_CR8","doi-asserted-by":"publisher","unstructured":"Zar, H. J. Advances in prevention of RSV disease in infants. Int. J Infect Dis. https:\/\/doi.org\/10.1016\/j.ijid.2025.107817 (2025).","DOI":"10.1016\/j.ijid.2025.107817"},{"key":"5586_CR9","doi-asserted-by":"publisher","unstructured":"Zar, H. J., & Stein, R. T. Maternal vaccination to prevent severe RSV disease in infants. Lancet Infect Dis. https:\/\/doi.org\/10.1016\/S1473-3099(25)00231-2 (2025).","DOI":"10.1016\/S1473-3099(25)00231-2"},{"key":"5586_CR10","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1002\/ppul.27310","volume":"60","author":"H Zar","year":"2024","unstructured":"Zar, H. New advances in RSV: Is prevention attainable?. Pediatr. Pulmonol. 60, S120\u2013S122 https:\/\/doi.org\/10.1002\/ppul.27310 (2024).","journal-title":"Pediatr. Pulmonol."},{"key":"5586_CR11","doi-asserted-by":"publisher","DOI":"10.69854\/jcq.2026.0001","author":"T Nosho","year":"2026","unstructured":"Nosho, T., Otsu, Y., Nomura, M. & Zhang, Y. Comparative effectiveness of monoclonal antibody prophylaxis for preventing severe respiratory syncytial virus infection in infants: a network meta-analysis. J. Clin. Quest. https:\/\/doi.org\/10.69854\/jcq.2026.0001 (2026).","journal-title":"J. Clin. Quest."},{"key":"5586_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/87551225251392119","volume":"42","author":"B Phillips","year":"2025","unstructured":"Phillips, B., Jackson, C. D. & Phillips, J. L. Clesrovimab for the prevention of respiratory syncytial virus lower respiratory tract disease in infants. J. Pharm. Technol. 42, 98\u2013104 https:\/\/doi.org\/10.1177\/87551225251392119 (2025).","journal-title":"J. Pharm. Technol."},{"key":"5586_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2576","volume":"34","author":"ATK Sevendal","year":"2024","unstructured":"Sevendal, A. T. K., Hurley, S., Bartlett, A., Rawlinson, W. D. & Walker, G. J. Systematic review of the efficacy and safety of RSV-specific monoclonal antibodies and antivirals in development. Rev. Med Virol. 34, e2576 https:\/\/doi.org\/10.1002\/rmv.2576 (2024).","journal-title":"Rev. Med Virol."},{"key":"5586_CR14","doi-asserted-by":"publisher","unstructured":"Sinha, A. et al. Evaluation of a monoclonal antibody against respiratory syncytial virus, clesrovimab, in infants and children: comprehensive rationale and study design for the late-stage clinical trials. Contemp Clin Trials. 107995, https:\/\/doi.org\/10.1016\/j.cct.2025.107995 (2025).","DOI":"10.1016\/j.cct.2025.107995"},{"key":"5586_CR15","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s40265-025-02224-7","volume":"85","author":"YY Syed","year":"2025","unstructured":"Syed, Y. Y. Clesrovimab: First approval. Drugs 85, 1487\u20131492, https:\/\/doi.org\/10.1007\/s40265-025-02224-7 (2025).","journal-title":"Drugs"},{"key":"5586_CR16","doi-asserted-by":"publisher","unstructured":"Tabulov, C. E., & Shaeer, K. M. Recent developments in pediatric respiratory syncytial virus prevention: the expanding role of monoclonal antibodies. Am. J. Health Syst. Pharm. https:\/\/doi.org\/10.1093\/ajhp\/zxaf019 (2026).","DOI":"10.1093\/ajhp\/zxaf019"},{"key":"5586_CR17","doi-asserted-by":"publisher","unstructured":"Venturella, F., Marino, G., & Pinto, A. The evolving science of clesrovimab: Pharmacological insights and clinical implications. J. Biol. Res. 14042 https:\/\/doi.org\/10.4081\/jbr.2026.14042 (2026).","DOI":"10.4081\/jbr.2026.14042"},{"key":"5586_CR18","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s40121-026-01311-w","volume":"15","author":"B Yarnoff","year":"2026","unstructured":"Yarnoff, B. et al. Cost-effectiveness of nirsevimab and clesrovimab in preventing respiratory syncytial virus lower respiratory tract disease in infants in the United States: A modeling study. Infect. Dis. Ther. 15, 1047\u20131073 https:\/\/doi.org\/10.1007\/s40121-026-01311-w (2026).","journal-title":"Infect. Dis. Ther."},{"key":"5586_CR19","doi-asserted-by":"publisher","unstructured":"Zar H. J. et al. Clesrovimab for prevention of RSV disease in healthy infants. N. Engl. J. Med. 393, 1292\u20131303 https:\/\/doi.org\/10.1056\/NEJMoa2502984 (2025).","DOI":"10.1056\/NEJMoa2502984"},{"key":"5586_CR20","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1913556","volume":"383","author":"MP Griffin","year":"2020","unstructured":"Griffin, M. P. et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N. Engl. J. Med. 383, 415\u2013425 https:\/\/doi.org\/10.1056\/NEJMoa1913556 (2020).","journal-title":"N. Engl. J. Med."},{"key":"5586_CR21","doi-asserted-by":"publisher","unstructured":"Munro, A. P. S. et al. 180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial. Lancet Child Adolesc. Health 9, 404\u2013412 https:\/\/doi.org\/10.1016\/S2352-4642(25)00102-6 (2025).","DOI":"10.1016\/S2352-4642(25)00102-6"},{"key":"5586_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/irv.70164","volume":"19","author":"M Wetzke","year":"2025","unstructured":"Wetzke, M. et al. Prevalence of resistance-associated mutations in RSV F protein against monoclonal antibodies prior to widespread implementation: Findings from a prospective German pediatric cohort. Influenza Other Respir. Viruses. 19, e70164 https:\/\/doi.org\/10.1111\/irv.70164 (2025).","journal-title":"Influenza Other Respir. Viruses."},{"key":"5586_CR23","doi-asserted-by":"publisher","unstructured":"Rostad, C. et al. Maternal RSV vaccination, infant nirsevimab, or both: Interim analysis of a randomized trial. Pediatrics 157, https:\/\/doi.org\/10.1542\/peds.2025-075223 (2026).","DOI":"10.1542\/peds.2025-075223"},{"key":"5586_CR24","doi-asserted-by":"publisher","unstructured":"Rajnik, M. & Ottolini M. Reducing the impact of RSV in infants: Vaccinate mothers, passively immunize newborns, or both? Pediatrics 157, https:\/\/doi.org\/10.1542\/peds.2025-075676 (2026).","DOI":"10.1542\/peds.2025-075676"},{"key":"5586_CR25","doi-asserted-by":"publisher","unstructured":"Valtuille, Z. et al. Effectiveness of nirsevimab immunisation after birth versus RSVpreF maternal vaccination in preventing RSV-related hospitalisations in infants: A population-based retrospective cohort study. Lancet Child Adolesc. Health. https:\/\/doi.org\/10.1016\/S2352-4642(26)00075-1 (2026).","DOI":"10.1016\/S2352-4642(26)00075-1"},{"key":"5586_CR26","doi-asserted-by":"publisher","unstructured":"Fridman, A. et al. Clesrovimab binding site conservation on the RSV F protein: an evaluation of RSV molecular sequencing data from 2019\u20132023 and GenBank sequence analysis. Open Forum Infect. Dis. 12, ofae631.2486 https:\/\/doi.org\/10.1093\/ofid\/ofae631.2486 (2025).","DOI":"10.1093\/ofid\/ofae631.2486"},{"key":"5586_CR27","doi-asserted-by":"publisher","unstructured":"Ares-G\u00f3mez, S. et al. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. Lancet Infect. Dis. 24, 817\u2013828 https:\/\/doi.org\/10.1016\/S1473-3099(24)00215-9 (2024).","DOI":"10.1016\/S1473-3099(24)00215-9"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05586-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05586-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05586-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:46:58Z","timestamp":1792108018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05586-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":27,"alternative-id":["5586"],"URL":"https:\/\/doi.org\/10.1038\/s41390-026-05586-0","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable (Perspective article).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}